dc.contributor.author | Çiftçiler, Rafiye | |
dc.contributor.author | Özenirler, Seren | |
dc.contributor.author | Atak Yücel, Ayşegül | |
dc.contributor.author | Cengiz, Mustafa | |
dc.contributor.author | Erkan, Gülbanu | |
dc.contributor.author | Büyükdemirci, Erkan | |
dc.contributor.author | Sönmez, Cemile | |
dc.contributor.author | Yılmaz Esendağlı, Güldal | |
dc.date.accessioned | 10.07.201910:49:13 | |
dc.date.accessioned | 2019-07-10T19:57:41Z | |
dc.date.available | 10.07.201910:49:13 | |
dc.date.available | 2019-07-10T19:57:41Z | |
dc.date.issued | 2017 | en_US |
dc.identifier.citation | Çiftçiler, R., Özenirler, S., Atak Yücel, A., Cengiz, M., Erkan, G., Büyükdemirci, E. … Yılmaz Esendağlı, G. (2017). The importance of serum biglycan levels as a fibrosis marker in patients with chronic hepatitis B. Journal of Clinical Laboratory Analysis, 31(5). https://dx.doi.org/10.1002/jcla.22109 | en_US |
dc.identifier.issn | 0887-8013 | |
dc.identifier.issn | 1098-2825 | |
dc.identifier.uri | https://dx.doi.org/10.1002/jcla.22109 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/3029 | |
dc.description | WOS: 000411716300040 | en_US |
dc.description | PubMed ID: 27925300 | en_US |
dc.description.abstract | BackgroundLiver biopsy is recommended in the majority of patients with chronic viral hepatitis for fibrosis evaluation. Because of the potential risks of liver biopsy, many studies related to non-invasive biomarkers of hepatic fibrosis have been performed. We aimed to assess the diagnostic value of serum biglycan as a non-invasive fibrosis marker in chronic hepatitis B patients. MethodsThis study included 120 patients with biopsy-proven hepatitis B patients and 60 healthy controls. Fibrosis stage and necroinflammatory activity were assessed in liver biopsy specimens. Biglycan level was measured using an ELISA assay. ResultsSerum biglycan levels of chronic hepatitis B patients were found to be significantly higher than those of healthy controls (337.3363.0pg/mL vs 189.1 +/- 61.9pg/mL, respectively, P<.001). There was a statistically significant positive correlation between serum biglycan level and fibrosis stage (P=.004; r=.213). Besides, a statistically significant positive correlation was found between serum biglycan level and necroinflammatory activity (P<.001; r=.271). The AUROC of BGN levels was 0.702 for fibrosis stage, differentiating patients from healthy controls with statistical significance (P<.001). The AUROC of BGN levels was 0.632 for necroinflammatory activity score, differentiating patients from healthy controls with statistical significance (P=.004). ConclusionsSerum biglycan might be used as a non-invasive marker of liver fibrosis. Further studies are needed to evaluate the usefulness of this marker. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Wiley | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Biglycan | en_US |
dc.subject | Chronic Hepatitis B | en_US |
dc.subject | Liver Biopsy | en_US |
dc.subject | Liver Fibrosis | en_US |
dc.subject | Non-Invasive Marker | en_US |
dc.title | The importance of serum biglycan levels as a fibrosis marker in patients with chronic hepatitis B | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Journal of Clinical Laboratory Analysis | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0002-1824-9934 | en_US |
dc.identifier.volume | 31 | en_US |
dc.identifier.issue | 5 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1002/jcla.22109 | en_US |
dc.identifier.wosquality | Q3 | en_US |
dc.identifier.scopusquality | Q2 | en_US |